Aurobindo Pharma shares extend losses after USFDA's OAI classification for subsidiary's plant
CNBC-TV18

Aurobindo Pharma said the USFDA had inspected the facility from August 17 to
August 21, 2026, and issued four observations following the inspection. The
company said it had responded to all four observations within the stipulated
time.







